



SHAREABLE PDF

The impact of different antibiotic treatment regimens on mortality in *Mycobacterium avium* complex pulmonary disease: a population-based cohort study

Sarah K. Brode^{1,2,3,4}, Hannah Chung⁴, Michael A. Campitelli⁴, Jeffrey C. Kwong^{4,5,6,7,8}, Rinku Sutradhar^{4,7}, Alex Marchand-Austin⁵, Kevin L. Winthrop⁹, Frances B. Jamieson^{5,10} and Theodore K. Marras^{1,2}

Affiliations: ¹Division of Respiriology, Dept of Medicine, University of Toronto, Toronto, ON, Canada. ²Dept of Medicine, University Health Network and Mount Sinai Hospital, Toronto, ON, Canada. ³Division of Respiratory Medicine, West Park Healthcare Centre, Toronto, ON, Canada. ⁴ICES, Toronto, ON, Canada. ⁵Public Health Ontario, Toronto, ON, Canada. ⁶Dept of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. ⁷Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. ⁸Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON, Canada. ⁹Oregon Health and Science University, Portland, OR, USA. ¹⁰Dept of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Correspondence: Sarah K. Brode, University Health Network and Mount Sinai Hospital, Dept of Medicine, Division of Respiriology, Toronto Western Hospital, 399 Bathurst St. 7E-453, Toronto, ON M5T 2S8, Canada. E-mail: sarah.brode@uhn.ca



@ERSpublications

No significant difference in mortality among patients treated with different antibiotic regimens for *Mycobacterium avium* pulmonary disease <https://bit.ly/3abXjDJ>

Cite this article as: Brode SK, Chung H, Campitelli MA, *et al.* The impact of different antibiotic treatment regimens on mortality in *Mycobacterium avium* complex pulmonary disease: a population-based cohort study. *Eur Respir J* 2020; 56: 1901875 [<https://doi.org/10.1183/13993003.01875-2019>].

This single-page version can be shared freely online.

To the Editor:

Evidence-based guidelines recommend the combination of macrolide–ethambutol–rifamycin as first-line treatment for *Mycobacterium avium* complex pulmonary disease (MAC-PD) [1]. Whether this regimen results in improved survival is unknown.